December 27, 2022
Juran Kato, PhD, president and CEO of GEXVal ., was invited by Kirin Holdings Company to give a lecture on drug discovery in rare diseases and venture ecosystem. Over 100 people joined on site at Kirin Central Institute or via online on December 2, 2022. Participants engaged in active discussions afterwards and exchanged different opinions on R&D, career, and work performance etc.
According to the post-event survey, 96% of the respondents rated the lecture as "very interesting" or "interesting". Regarding the impact of the presentation, more than 60% of the respondents answered that they individually thinks "the lecture has major impact" or "has impact" to future work behavior.
GEXVal strives to generate extra value to deliver cost-effective, innovative treatment options to improve health and QoL of patients and families affected by rare and intractable diseases.
For further information, please contact us: firstname.lastname@example.org